Patents Assigned to Synthorx, Inc.
  • Publication number: 20240082359
    Abstract: Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
    Type: Application
    Filed: June 1, 2023
    Publication date: March 14, 2024
    Applicant: Synthorx, Inc.
    Inventors: Jerod PTACIN, Carolina E. CAFFARO, Marcos MILLA
  • Patent number: 11919934
    Abstract: Disclosed herein are interleukin (IL) 15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: March 5, 2024
    Assignee: SYNTHORX, INC.
    Inventors: Carolina E. Caffaro, Jerod Ptacin, Marcos Milla
  • Publication number: 20240043823
    Abstract: Disclosed herein are methods, compositions and kits for the synthesis of proteins which comprises unnatural amino acids that utilize a mutant tRNA.
    Type: Application
    Filed: October 4, 2023
    Publication date: February 8, 2024
    Applicants: Synthorx, Inc., The Scripps Research Institute
    Inventors: Jerod PTACIN, Carolina CAFFARO, Hans AERNI, Yorke ZHANG, Emil C. FISCHER, Aaron W. FELDMAN, Vivian T. DIEN, Floyd E. ROMESBERG
  • Publication number: 20230416327
    Abstract: Disclosed herein are methods and uses relating to administering IL-2 conjugates or methods useful for the treatment of one or more indications, such as the treatment of proliferative diseases. Also described herein are pharmaceutical compositions and kits comprising one or more of the IL-2 conjugates.
    Type: Application
    Filed: April 6, 2023
    Publication date: December 28, 2023
    Applicant: Synthorx, Inc.
    Inventors: Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Laura SHAWVER
  • Patent number: 11834689
    Abstract: Disclosed herein are methods, compositions and kits for the synthesis of proteins which comprises unnatural amino acids that utilize a mutant tRNA.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: December 5, 2023
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, SYNTHORX, INC.
    Inventors: Jerod Ptacin, Carolina Caffaro, Hans Aerni, Yorke Zhang, Emil C. Fischer, Aaron W. Feldman, Vivian T. Dien, Floyd E. Romesberg
  • Publication number: 20230302089
    Abstract: Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
    Type: Application
    Filed: March 6, 2023
    Publication date: September 28, 2023
    Applicant: Synthorx, Inc.
    Inventors: Carolina E. CAFFARO, Marcos MILLA, Jerod PTACIN
  • Publication number: 20230277627
    Abstract: Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with pembrolizumab.
    Type: Application
    Filed: April 6, 2023
    Publication date: September 7, 2023
    Applicant: Synthorx, Inc.
    Inventors: Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Laura SHAWVER
  • Patent number: 11701407
    Abstract: Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: July 18, 2023
    Assignee: SYNTHORX, INC.
    Inventors: Jerod Ptacin, Carolina E. Caffaro, Marcos Milla
  • Patent number: 11622993
    Abstract: Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: April 11, 2023
    Assignee: SYNTHORX, INC.
    Inventors: Jerod Ptacin, Carolina E. Caffaro, Marcos Milla
  • Publication number: 20220324792
    Abstract: Disclosed herein are methods of preparing N6-((2-azidoethoxy)carbonyl)lysine, N6-((2-azidoethoxy)carbonyl)-L-lysine, and N6-((2-azidoethoxy)carbonyl)-D-lysine. Also disclosed herein are the compounds tert-butyl N2-(tert-butoxycarbonyl)-N6-((2-chloroethoxy)carbonyl)-L-lysinate and tert-butyl N6-((2-azidoethoxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-lysinate, and uses thereof.
    Type: Application
    Filed: June 21, 2022
    Publication date: October 13, 2022
    Applicant: Synthorx, Inc.
    Inventors: Hans AERNI, Randall SCHEUERMAN, Nikolai F. SEPETOV, Alexander V. SHIROKOV
  • Publication number: 20220273767
    Abstract: Disclosed herein are interleukin 10 (IL-10) conjugates and uses in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the IL-10 conjugates.
    Type: Application
    Filed: May 3, 2022
    Publication date: September 1, 2022
    Applicant: Synthorx, Inc.
    Inventors: Carolina E. CAFFARO, Jerod PTACIN, Marcos MILLA
  • Publication number: 20220016249
    Abstract: Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
    Type: Application
    Filed: June 17, 2021
    Publication date: January 20, 2022
    Applicant: Synthorx, Inc.
    Inventors: Jerod Ptacin, Carolina E. Caffaro, Marcos Milla
  • Publication number: 20220016252
    Abstract: Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with an anti-EGFR antibody.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 20, 2022
    Applicant: Synthorx, Inc.
    Inventors: Giovanni ABBADESSA, Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Timothy R. WAGENAAR
  • Publication number: 20210338829
    Abstract: Disclosed herein are interleukin 10 conjugates and uses in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the IL-10 conjugates.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 4, 2021
    Applicant: Synthorx, Inc.
    Inventors: Carolina E. CAFFARO, Jerod PTACIN, Marcos MILLA
  • Patent number: 11077195
    Abstract: Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: August 3, 2021
    Assignee: SYNTHORX, INC.
    Inventors: Jerod Ptacin, Carolina E. Caffaro, Marcos Milla
  • Publication number: 20210070827
    Abstract: Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
    Type: Application
    Filed: September 9, 2020
    Publication date: March 11, 2021
    Applicant: Synthorx, Inc.
    Inventors: Jerod PTACIN, Carolina E. CAFFARO, Marcos MILLA
  • Publication number: 20210054040
    Abstract: Disclosed herein are interleukin (IL)-15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates. In some embodiments, at least one amino acid residue in the IL-15 conjugate is replaced by the structure of Formula (I) described herein.
    Type: Application
    Filed: August 21, 2020
    Publication date: February 25, 2021
    Applicant: Synthorx, Inc.
    Inventors: Carolina E. CAFFARO, Jerod PTACIN, Marcos MILLA
  • Publication number: 20210046160
    Abstract: Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) in combination with other agents or methods useful for the treatment of one or more indications, such as the treatment of proliferative diseases. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
    Type: Application
    Filed: August 14, 2020
    Publication date: February 18, 2021
    Applicant: Synthorx, Inc.
    Inventors: Jerod PTACIN, Carolina E. CAFFARO, Marcos MILLA
  • Publication number: 20200399338
    Abstract: Disclosed herein are interleukin (IL) 15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates.
    Type: Application
    Filed: August 25, 2020
    Publication date: December 24, 2020
    Applicant: Synthorx, Inc.
    Inventors: Carolina E. CAFFARO, Jerod PTACIN, Marcos MILLA
  • Publication number: 20200330601
    Abstract: Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
    Type: Application
    Filed: July 1, 2020
    Publication date: October 22, 2020
    Applicant: Synthorx, Inc.
    Inventors: Jerod PTACIN, Carolina E. CAFFARO, Marcos MILLA